Alendro

Quick links to important sections

Alendro

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alendro

Property Description
Active Ingredient Alendronate Sodium
Form Oral tablet or Oral solution
Pharmacological Class Bisphosphonate, specifically a Nitrogen-containing Bisphosphonate
General Purpose Inhibition of bone breakdown (resorption)
Origin Synthetic compound

What Type of Medicine is Alendro (Alendronate)?

Alendro is a medicine containing the active ingredient Alendronate Sodium, which is classified as a Bisphosphonate. This chemical group consists of synthetic compounds designed to inhibit bone loss, a mechanism recognized for its role in managing skeletal integrity. Alendronate Sodium is specifically a nitrogen-containing bisphosphonate, distinguishing it structurally from older bisphosphonates and contributing to its pharmacological potency in affecting the skeleton. Its status as a single-ingredient product ensures a targeted, non-hormonal approach to supporting bone structure.

Composition and Available Oral Forms

The core composition of this medicine is the active substance, Alendronate Sodium, formulated for oral consumption. The drug is supplied for the oral route of administration in two primary dosage form(s): a conventional tablet and an oral solution. The availability of the liquid form provides flexibility for patients who may have difficulty swallowing tablets, while still delivering the same active chemical compound. The composition relies on standard pharmaceutical excipients (for tablets) or an aqueous base (for the liquid form) to ensure stability and delivery of the active agent.

General Purpose and Mechanism of Bone Resorption Inhibition

The general purpose of Alendronate is to support the strength and structural stability of the skeleton by acting as a Bone Resorption Inhibitor. It achieves this by binding directly to the mineralized surfaces of the bone. By selectively targeting and inhibiting the activity of osteoclasts—the cells naturally responsible for clearing away old bone—Alendronate shifts the natural bone turnover balance. This action results in the preservation of existing bone structure, which is the foundational benefit, facilitating a net increase in overall bone mineral density (BMD) over time.

Regulatory References

  1. NIH: Alendronate Sodium Information

What side effects are possible with Alendro?

Possible Side Effects and Safety Information

The safety profile for Alendro is primarily characterized by the risk of upper gastrointestinal (GI) irritation and rare, but serious, musculoskeletal and skeletal risks.

Common Adverse Reactions

Clinical trials have reported the most common adverse reactions (ge 3%) as gastrointestinal events, including abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, and nausea. Musculoskeletal pain (bone, joint, and/or muscle pain) is also frequently reported, sometimes severe.

Serious and Clinically Significant Risks

Serious adverse reactions reported in regulatory documents include:

  • Severe Esophageal Events: Alendro can cause local irritation of the upper GI mucosa, leading to esophagitis, esophageal ulcers, or erosion, which in rare instances may progress to esophageal stricture. This risk is minimized by strict adherence to administration instructions.
  • Osteonecrosis of the Jaw (ONJ): Rare cases of ONJ, often associated with local infection, tooth extraction, and/or delayed healing, have been reported, primarily in post-marketing surveillance.
  • Atypical Femoral Fractures: Subtrochanteric and diaphyseal femoral fractures have been reported, particularly with long-term bisphosphonate use. Prodromal pain in the thigh or groin may precede a complete fracture.
  • Severe Musculoskeletal Pain: This pain can be severe and may warrant discontinuation of the medication.
  • Hypocalcemia: Low blood calcium levels may occur, and pre-existing hypocalcemia must be corrected prior to initiating therapy.

Safety Restrictions and Monitoring

Alendro is contraindicated in patients with abnormalities of the esophagus (e.g., stricture, achalasia) that delay emptying, or in those unable to stand or sit upright for at least 30 minutes. It is also contraindicated in patients with hypocalcemia or severe renal impairment (creatinine clearance <35 mL/min). Caution is advised in patients with active upper GI disease. Monitoring for new hip, thigh, or groin pain is required to evaluate the possibility of an incomplete femoral fracture.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that oral overdosage with Alendronate may result in two primary types of adverse events: severe upper gastrointestinal distress and systemic metabolic changes.

Overdose Manifestations Description (Label-Documented)
Gastrointestinal Effects Upset stomach, heartburn, esophagitis, gastritis, or ulcer. Potential complications include signs of upper GI bleeding, such as bloody vomit or black stools.
Metabolic Effects Development of hypocalcemia (low calcium levels) and hypophosphatemia (low phosphate levels).

Emergency Response and Required Actions

When an overdose is suspected, immediate medical attention must be sought, and the regional Poison Control Center should be contacted for urgent management advice. The drug's regulatory documentation specifies several procedural steps for initial care:

  • Supportive Measure: Milk or antacids should be administered to help bind the Alendronate and minimize its absorption.
  • Specific Warning: Vomiting should not be induced due to the risk of worsening esophageal irritation, and the patient must remain fully upright.
  • Monitoring: Monitoring of serum calcium and phosphate levels is necessary to manage metabolic shifts.

There is no specific antidote documented for Alendronate overdose. For patients with severe kidney impairment, the elimination of the drug may be reduced, which is a key factor in managing an overdose situation.

Therapeutic Uses of Alendro

Main Uses and Therapeutic Benefits of Alendronate

Alendronate is commonly used in therapeutic contexts that involve several key conditions. The medication may be part of therapeutic management for the treatment and support of bone density to address osteoporosis in postmenopausal women, the support to increase bone mass in men with osteoporosis, and the treatment of glucocorticoid-induced osteoporosis in both men and women.


Supporting Skeletal Integrity and Functional Stability

Alendronate is commonly used in therapeutic management for conditions characterized by low Bone Mineral Density (BMD), which represents structural weakness. The medication is used to support bone strength in patient groups where bone loss is common. The primary therapeutic goal for patients is to reduce the risk of fracture, which are common manifestations of skeletal fragility.

“The medication may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

In postmenopausal women with osteoporosis, the medication helps increase bone mass and may contribute to a lower incidence of fractures, including those of the hip and spine. The drug is also used in managing Paget's disease of bone, where it assists in addressing disorganized bone turnover, which may help to ease related symptoms like bone pain and prevent the progression of bony deformities.


Quick Fact: Relief for Fracture Risk This medication is commonly used to help with the long-term management of chronic bone disorders, supporting patients by contributing to a reduction in the risk of future fractures.

Eligibility and Restrictions for Use

Who Can and Cannot Use Alendronate (Alendro)

Official regulatory information strictly defines the eligible population for Alendronate based on medical status, physical ability, and specific organ function, and is intended primarily for adult men and postmenopausal women with specific bone conditions.


Contraindications and Absolute Restrictions

Use of Alendronate is contraindicated and must not occur if a patient presents with the following conditions, as these are absolute prohibitions defined by regulatory labeling:

  • Hypocalcemia: Low levels of calcium in the blood.
  • Esophageal Abnormalities: Conditions such as achalasia or stricture that delay the emptying of the esophagus.
  • Physical Incapacity: Inability to stand or sit upright for at least 30 minutes after taking the dose.
  • Hypersensitivity: Known allergy to Alendronate Sodium or any component.

Use Restrictions and Limitations

Population Group Regulatory Status
Severe Renal Impairment (Creatinine Clearance < 35 mL/min) Not Recommended due to limited clinical experience.
Pediatric Patients (under 18 years) Not Indicated or recommended.
Pregnant or Nursing Women Not Recommended due to insufficient data.
Active GI Problems (e.g., ulcers, gastritis) Use with Caution advised; risk of worsening condition.

No dosage adjustment is necessary for older adults or patients with hepatic (liver) impairment based on age or liver function alone.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Alendronate's interaction profile is primarily defined by its absorption constraints in the gastrointestinal tract and its lack of systemic metabolism.

Absorption-Related Interactions

The most clinically significant interactions result from Alendronate forming non-absorbable complexes with multivalent cations. This interaction severely reduces the amount of medication available to the body.

Interacting Substance Category Practical Implication Regulatory Basis of Interaction
Multivalent Cations (e.g., Calcium, Iron, Magnesium) Must be separated in time to prevent binding and loss of Alendronate absorption. Chemical Chelation
Food and Beverages (other than plain water) Substantial reduction in bioavailability; requires administration at least 30 minutes before the first food or drink of the day. Reduced Absorption
Antacids and Supplements Must be avoided immediately following Alendronate. Chelation and Reduced Absorption

Pharmacodynamic Interactions

Caution is advised when co-administering Alendronate with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin. This combination may increase the risk of adverse reactions in the upper gastrointestinal tract due to the potential for additive mucosal irritation.

Metabolic Interactions

Alendronate is not metabolized by the body's major enzyme system, including the cytochrome P450 enzymes. Therefore, it is not expected to interfere with the clearance or plasma concentrations of other medications based on these metabolic pathways. Use in patients with severe renal impairment (creatinine clearance less than 35 mL/min) is not recommended due to a lack of data on drug clearance in this population.

Mechanism of Action

Selective Localization at Active Bone Resorption Sites

This domain covers the initial, targeted action of the molecule: its chemical binding to the hydroxyapatite mineral component of the bone matrix. This mechanism ensures the compound is concentrated only at bone surfaces undergoing active breakdown, which is essential for subsequent cellular uptake and the resulting physiological suppression of bone resorption.

Intracellular Metabolic Pathway Blockade

This domain focuses on the molecular cascade inside the osteoclast (the bone-resorbing cell). Once internalized, the drug functions as an inhibitor of the enzyme Farnesyl Diphosphate Synthase (FPPS) within the Mevalonate pathway. This inhibition disrupts the synthesis of key cellular lipids, which in turn leads to the collapse of the cell's cytoskeleton and the subsequent programmed death (apoptosis) of the osteoclast.

️ Uncoupling of Bone Resorption and Formation

This domain describes the final system-level consequence: the suppression of the bone breakdown phase while the bone-building cells remain relatively functional. By reducing the number and activity of bone-resorbing cells, the mechanism leads to a shift in the bone turnover balance where resorption activity is suppressed. This uncoupling establishes a state where bone formation continues without corresponding bone resorption, leading to the retention of bone mass.

Dosage and Administration Information

Administration Guidelines for Alendronate

The usage of Alendronate follows specific procedures focusing on the oral route of administration via tablets, oral solutions, or effervescent tablets. Dosing regimens are standardized to address chronic bone conditions.


Labeled Dosing Schedules

Regimen Dose Standard Frequency
Treatment of Osteoporosis 10 mg or 70 mg Once Daily or Once Weekly
Prevention of Osteoporosis 5 mg or 35 mg Once Daily or Once Weekly
Paget's Disease of Bone 40 mg Once Daily for 6 months

Key Administration Steps and Constraints

To ensure adequate absorption and proper transit to the stomach, the medicine must be taken only with plain water (not mineral water, coffee, or juice). The administration is conditional on the following protocol:

  1. Timing: Take the dose immediately upon arising for the day, at least 30 minutes before any food, beverage, or other medication.
  2. Posture: The patient must remain fully upright (sitting or standing) for a minimum of 30 minutes after taking the dose, and until after the first food of the day.
  3. Preparation: Tablets must be swallowed whole and not chewed, crushed, or dissolved in the mouth. Effervescent tablets must be fully dissolved in room-temperature plain water before ingestion.

No dosage adjustment is recommended for older adults or in mild-to-moderate renal impairment (creatinine clearance 35 to 60 mL/min), but use is generally not recommended in severe renal impairment. If a weekly dose is missed, one dose is taken the morning after remembering, and the original schedule is resumed the following week; two doses must never be taken on the same day.

Recent Clinical Evidence

Research Evidence Overview for Alendro


Evidence for use in Postmenopausal Osteoporosis

The compound was studied for women following menopause. Research examined populations with changes in bone density, which is a condition marked by functional limitations. This was primarily evaluated through randomized controlled trials (RCTs), which are studies where participants are randomly assigned to receive either the studied compound or a comparison (often a placebo) over defined time intervals. These studies were used in research exploring how symptoms change over time related to bone density and fracture occurrence.

Studies report how bone density measurements evolved in the observed populations in the spine and hip. Research also examined and monitored reported outcomes related to the incidence of certain fractures (such as hip and vertebral fractures) during the study period. Findings describe patterns observed in the studies. What remains uncertain is the long-term characterization of these outcomes, particularly those that extend beyond the duration of the major trials (often 3 to 5 years). The results apply only to the populations studied, and certainty remains low regarding the full range of long-term effects.

Evidence for use in Male Osteoporosis

Alendro was studied for men with osteoporosis, a condition marked by functional limitations. Studies explored the compound's influence on bone mineral density using similar measures as those in postmenopausal women. The research examined changes measured during the study period, often involving short-term symptom changes related to bone health. The data show patterns related to measured bone mineral density in the men studied. Findings indicate observed differences in bone density measurements between the studied group and the control group. Evidence contributes to understanding symptom patterns in this specific population. Comparative evidence is lacking, and the data for this group remain limited. Follow-up durations were limited in some of these trials, meaning the long-term effects are not fully established for men.


Evidence in Special Populations

The research has examined Alendro in certain special populations where the evidence may be more limited. This includes older adults (for example, those ge 75 years) and individuals with some level of reduced kidney function. The compound was evaluated in settings where symptoms may vary in intensity due to comorbid conditions. Subgroup findings are uncertain, and data for certain groups remain insufficient, specifically concerning outcomes for children or adolescents, as most studies focused on adult populations. The results apply only to the populations studied, and comparative evidence is lacking for these groups.

What is still Uncertain about Alendro

Research is ongoing, and several key areas remain uncertain about Alendro. Follow-up durations were limited in many primary trials, meaning the long-term effects are not fully established. The evidence quality varies across studies, leading to mixed findings in certain sub-analyses. Comparative evidence is lacking in some areas, meaning direct, head-to-head research with all other available compounds is not consistently available. Subgroup findings are uncertain, particularly regarding very specific populations or those with multiple comorbid conditions. The available data provide context but not individual predictions, and evidence highlights what is known — and what is still uncertain regarding outcomes.

Frequently Asked Questions (FAQ)

Common questions about Alendro (FAQ)

Q: Do older adults tolerate Alendro well?

A: According to official product information, clinical studies have not shown an age-related difference in the overall effectiveness or safety profile of Alendronate in older adults compared to younger adults. Therefore, no dosage adjustment is typically necessary for elderly patients based on age alone.


Q: Is Alendro considered a long-term treatment?

A: Regulatory guidelines indicate that the need for continued therapy requires periodic re-evaluation by a healthcare provider, especially after five or more years of use, as the optimal duration of treatment with bisphosphonates has not been fully established.


Q: Is Alendro available over the counter?

A: Official information confirms that Alendronate is a prescription-only medicine. It is made available with a prescription from a licensed healthcare provider.


Q: Is it necessary to take calcium and Vitamin D with Alendro?

A: Regulatory information advises that patients should receive supplemental calcium and Vitamin D if their dietary intake is insufficient. The correction of any pre-existing low calcium levels (hypocalcemia) is required before initiating Alendronate therapy.


Q: Do you need a special diet while on Alendro?

A: The administration guidelines for Alendronate are very strict regarding food and drink timing. To ensure proper absorption, the medicine must be taken only with plain water and at least 30 minutes before any food, beverage, or other medicine of the day. This restriction is essential to ensure proper absorption and effectiveness of the medication.


Q: How long does it take for Alendro to start working?

A: Studies and official information indicate that the medicine begins working rapidly by reducing the rate of bone breakdown (resorption). Significant increases in bone mineral density (BMD) were typically observed in clinical studies after 12 months of treatment.


Q: Does Alendro cause dizziness or tiredness?

A: Reported adverse reactions listed in the official product information include central nervous system effects such as dizziness, a spinning sensation (vertigo), and general weakness or lack of energy (malaise). These effects have been reported by patients taking Alendronate.


Q: Is Alendro safe for people with heart conditions?

A: Official warnings note that Alendronate requires caution in patients with a history of heart failure, heart or blood vessel problems, or high blood pressure. This is particularly relevant for certain formulations that contain sodium.


Q: Can Alendro be stopped suddenly?

A: Official guidelines state that the continuation or cessation of treatment requires periodic review by a healthcare provider. The product label specifies that discontinuation and immediate medical attention are necessary if a patient develops new or worsening symptoms of severe esophageal irritation.


Q: How long after starting Alendro should I expect a bone density change?

A: According to the official clinical pharmacology data, substantial changes in bone mineral density (BMD)—a key measure of the drug's effectiveness—were typically seen after 12 months of continuous treatment in clinical studies.


Q: Are there any long-term monitoring tests required while on Alendro?

A: The maintenance of adequate calcium and vitamin D intake is necessary during therapy. Additionally, the product label indicates that patients who develop new pain in the thigh or groin require immediate evaluation to rule out an incomplete femoral fracture.


Q: Does Alendro have any connection to hair loss?

A: Regulatory documents list hair loss (alopecia) as one of the reported adverse reactions based on post-marketing data.


Q: Does alcohol affect Alendro?

A: Official administration rules mandate that no beverage other than plain water be consumed for at least 30 minutes after taking Alendronate. Alcohol and other drinks may reduce the absorption of the medicine, potentially making it less effective.


Q: What is the duration of the effect of Alendro after stopping use?

A: Studies and regulatory information show that Alendronate has a long residual effect on bone after treatment is stopped. This is because the drug binds strongly to the bone mineral, meaning its anti-resorptive action can continue for many months after the last dose.


Q: Is Alendro an anti-inflammatory drug?

A: No. Official documents classify Alendronate as a bisphosphonate. Its purpose is to act as a specific inhibitor of osteoclast-mediated bone resorption (bone breakdown) and is not classified as an anti-inflammatory drug.

How should Alendro be stored and disposed of?

Alendronate must be stored and disposed of strictly according to the procedures documented in official regulatory labeling to maintain stability and safety.

Official Storage and Handling

Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, typically 59 F to 86 F (15 C to 30 C).
Protection Keep the medicine away from excess heat, moisture, and direct light; keep from freezing and away from heat.
Packaging Store in a tightly closed container. Effervescent tablets must remain in the original blister pack until the time of use.

Disposal and Child Safety

Requirement Official Regulatory Statement
Child Safety Keep this and all medications out of the reach of children. Must be dispensed with a child-resistant closure.
Disposal Rule Discard all expired medicines or medicine no longer needed; consult a healthcare professional for specific disposal methods.

The regulatory profile dictates that the product must be preserved within a defined thermal range and protected from environmental factors to ensure quality, and mandates the primary safety rule of restricted access for children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alendro found in:

A-Z Index: